7:30 am Registration & Morning Coffee
8:20 am Chair’s Opening Remarks
ADVANCING & ADOPTING NOVEL TECHNOLOGIES IN THE RETINAL IMAGING BIOMARKER SPACE
8:30 am Panel Discussion: Evaluating the Current State of Play of Retinal Imaging Technologies Available for Ophthalmic Drug Developers
Synopsis
- Evaluating how novel imaging modalities are being used to establish new and improved biomarkers for retinal disorders
- Unleashing the potentials of higher resolution technologies to translate into useful tools to determine disease activity and therapeutic efficacy
- Assessing the ability of novel technologies to validate retinal biomarkers for preclinical and clinical studies
MAXIMIZING AI TECHNOLOGY CAPABILITIES TO DRIVE RETINAL DRUG DEVELOPMENT
9:00 am Artificial Intelligence in Clinical Trials for Retinal Diseases
Synopsis
- Key challenges in the clinical development of new therapies for vision threatening retinal diseases
- Potential implementation of artificial-intelligence based tools and best practices in clinical trials
- Harnessing the power of artificial intelligence and advanced analytics to improve patient outcomes in randomized controlled trials for retinal diseases
9:30 am Achieving Transparency, Traceability and Reproducibility in Ocular AI/ML and Biomarker Development
Synopsis
- Ingest images and data into model-based data lake with ocuVault™
- Curate images into meaningful and reusable Collections with ocuLink™
- Train and Validate AI/ML algorithms with user-defined Annotation Palettes and traceable Projects in ocuLink™
9:40 am Speed Networking & Morning Coffee Break
Synopsis
As increasing numbers of companies emerge into the ophthalmology space, this is your optimal chance to network with this expanding community and learn how your peers are leveraging innovative imaging technologies for retinal therapeutic research. Connect with experts across discovery, preclinical and clinical development to collaboratively discuss future prospects for ophthalmic drug development.
10:45 am Determining Future Capabilities of AI to Optimize Opportunities for Advanced Retinal Imaging [Virtual]
Synopsis
• Forecasting the evolutionary nature of AI to establish real world outcomes in the future
• Leveraging the potentials of AI to correlate retinal images and function in geographic atrophy drug development
• Striving for FDA approval of AI-embedded devices to develop anatomical biomarkers
11:15 am From Clinical to Subclinical Biomarkers in Retinal Diseases Using AI Tools
Synopsis
- To identify the primary morphological events in AMD conversion
- Monitor individual disease activity in GA and MNV
- Differentiate between therapeutic effects on photoreceptor degeneration and RPE loss
- Develop a model to predict progression and therapeutic response based on OCT-based AI (research use only AI models)
11:45 am Leveraging AI for Prognostic Predictions of Geographic Atrophy Growth to Improve Clinical Trial Design
Synopsis
• Development and use of deep learning models for geographic atrophy growth rate prediction
• Interpreting deep learning models for biomarker discovery
12:15 pm Lunch & Networking Break
RETINAL IMAGING ENDPOINTS: THE PATIENT PERSPECTIVE
1:15 pm Patient Led Perspective on Real-Life Impacts of Advancing Retinal Imaging Innovations [Virtual]
Synopsis
- Current challenges with Endpoints and Outcome Measures from a patient perspective
- Retinal Imaging Endpoints as an opportunity to accelerate clinical development
- Patients as partners to drive innovation in Retinal Imaging Endpoints
BENCHMARKING RETINAL IMAGING TECHNIQUES FOR DEVELOPING BIOMARKERS OF DISEASE PROGRESSION & DRUG EFFICACY
1:45 pm Implementing a Single-Cell Molecular Imaging Approach to Demonstrate Drug Efficacy & Patient Response
Synopsis
- Harnessing DARC technology to detect early therapeutic efficacy in phase 1b studies for glaucoma and dry AMD
- Deploying DARC technology to predict retinal cell health and rate of disease progression
- Exploring patient populations to identify those with highest sensitivity to DARC
2:15 pm Icare Clinical Trial Toolkit from Anatomy to Function
Synopsis
• Improvements in True Color Retinal Imaging
• Microperimetry
• IOP monitoring
• Color Fundus Autofluorescence
2:25 pm Leveraging Retinal Imaging Modalities to Measure Success of Optogenetic Therapy
Synopsis
- Deploying OCT-guided multi-color variable spot ERG for spatially selected and integrated signal detection from optogenetically treated retina
- Leveraging OCT to quantify structural changes in retina due to optogenetic therapy
- Measuring functional optogenetically-sensitized retinal cell changes upon light stimulation with optoretinography
2:55 pm Afternoon Break
3:30 pm Optimizing Approaches to Visualize Diabetic Retinopathy & Clinically Measure Therapeutic-Induced Changes in Blood Flow
Synopsis
- Adopting multimodal imaging technologies to facilitate clinical advancements in diabetic retinopathy
- Leveraging IVFA and OCTA to detect and manage diabetic retinopathy
- Comparing abilities of different imaging modalities to develop non-invasive vascular based biomarkers
4:00 pm Optimizing Imaging Biomarkers of Diabetic Retinopathy & AMD to Support Clinical Trials
Synopsis
- Progressing from colour fundus photography to the modified DRSS to optimize assessment of diabetic retinopathy severity levels
- Evaluating the use of image-derived biomarkers in UW-FA and OCTA to detect retinal perfusion levels
- Obtaining accurate measurements of GA lesion size reduction and photoreceptor loss with imaging analysis
4:30 pm Evaluating Drug Safety & Patient Enrolment With Imaging to Progress Clinical Development of AMD Therapeutics
Synopsis
- Utilizing OCT and OCTA biomarkers to assess early therapeutic response
- Imaging small patient populations for signs of efficacy to inform phase 2 trial design
- Ensuring enrolment of the optimal patients with careful imaging strategies
5:00 pm Chair’s Closing Remarks & Happy Hour at the Bar
6:00 pm End of Day One
